Clinical Trials Browser

Phase 3 × Not yet recruiting × Cisplatin × Clear all

NCT07383116 2026-02-03

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Non Squamous Non-small Cell Lung Cancer

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07371897 2026-01-28

SHINE

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Cancinoma (NPC)

NCT07125755 2025-08-15

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

Squamous Cell Cancer of Head and Neck (SCCHN)

NCT06970782 2025-05-21

KYLIN-3

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06333821 2024-03-27

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Phase 3 Not yet recruiting

Uterine Cervical Neoplasms

NCT05767892 2023-04-05

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Phase 3 Not yet recruiting

Recurrence

NCT04465968 2020-07-10

DEEP_OCEAN

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Pancoast Syndrome

NCT03503136 2018-05-11

NX-NPC

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma